Date published: 2025-9-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olfr1012 Activators

The chemical activators of Olfr1012, a G protein-coupled receptor (GPCR) involved in olfactory signaling, function through various mechanisms to enhance its activity. Forskolin, directly activating adenylate cyclase, leads to an increase in cAMP levels, which in turn activates PKA. PKA phosphorylates substrates in GPCR signaling, thus enhancing the functionality of Olfr1012. Similarly, IBMX, a non-specific phosphodiesterase inhibitor, and Rolipram, a specific phosphodiesterase-4 inhibitor, result in cAMP accumulation, indirectly potentiating Olfr1012 activity through the cAMP pathway, crucial to GPCR function. Adrenergic agonists such as Epinephrine and Norepinephrine, and the beta-adrenergic agonist Isoproterenol, also contribute to this cAMP-mediated enhancement. Additionally, Cholera Toxin, prolonging cAMP elevation through ADP-ribosylation of the Gs alpha subunit, and Pertussis Toxin, inhibiting Gi alpha subunits, further support this mechanism of Olfr1012 activation.

Furthermore, Prostaglandin E2, acting on G protein-coupled EP receptors, and Histamine, through H2 receptors, elevate intracellular cAMP levels, thus facilitating Olfr1012 activation. The action of Adenosine on its GPCRs and Dopamine on D1-like receptors also leads to increased cAMP, enhancing Olfr1012's GPCR-related activity. Collectively, these activators demonstrate the complex regulation of GPCRs like Olfr1012, where multiple extracellular signals can converge on a common intracellular messenger, cAMP, culminating in the potentiation of the receptor's role in olfactory signaling. This intricate network of biochemical pathways underscores the nuanced nature of GPCR modulation and the diverse mechanisms through which Olfr1012's activity is enhanced.

SEE ALSO...

Items 11 to 11 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rolipram

61413-54-5sc-3563
sc-3563A
5 mg
50 mg
$75.00
$212.00
18
(1)

Rolipram, a phosphodiesterase-4 inhibitor, leads to increased cAMP levels, indirectly enhancing Olfr1012 activity in the GPCR-associated signaling pathway.